Business Context and Reporting Period
This Form 8-K is a current report filed by Veracyte, Inc. on November 13, 2014, covering events that occurred on November 11, 2014. The filing addresses changes to the Company's Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. It is a corporate governance report.
Material Changes
- Resignation: Samuel D. Colella notified the Board of his resignation, effective November 30, 2014. Mr. Colella served on the Board and the Compensation Committee.
- Election: The Board elected John L. Bishop to the Board of Directors, effective December 1, 2014. Mr. Bishop will also serve on the Compensation Committee.
- Background: Mr. Bishop is the Chairman and CEO of Cepheid, a global molecular diagnostics company. He previously served as a director of Conceptus, Inc. and is Chairman of AdvaMedDx.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Regarding compensation, Mr. Bishop will receive the same cash and equity compensation as other non-employee directors, as detailed in the Company's 2014 proxy statement.
Investor Verification Checklist
- Verify the effective dates of the director transition (Colella: Nov 30, 2014; Bishop: Dec 1, 2014).
- Review the Company's 2014 proxy statement for details on non-employee director compensation.
- Check the press release dated November 12, 2014 (Exhibit 99.1) for additional context on the Board changes.